Wenyue Zhou Yuwen Zhou Cheng Yi Xinyao Shu Guixia Wei Xiaorong Chen Xudong Shen Meng Qiu
10.3389/fimmu.2021.749204
Front Immunol
2021 Sep 29;12:749204.
msi-h/dmmr case report gastrointestinal cancer hyperprogression immune checkpoint inhibitors
CC BY
https://pubmed.ncbi.nlm.nih.gov/34659249/
Gastrointestinal Neoplasms / drug therapy Gastrointestinal Neoplasms / genetics Gastrointestinal Neoplasms / immunology Gastrointestinal Neoplasms / pathology Immune Checkpoint Inhibitors / therapeutic use Nivolumab / therapeutic use Programmed Cell Death 1 Receptor / antagonists & inhibitors
Gastrointestinal Neoplasms / drug therapy Gastrointestinal Neoplasms / genetics Gastrointestinal Neoplasms / immunology Gastrointestinal Neoplasms / pathology Immune Checkpoint Inhibitors / therapeutic use Nivolumab / therapeutic use Programmed Cell Death 1 Receptor / antagonists & inhibitors Case Reports B7-H1 Antigen / immunology DNA Mismatch Repair Disease Progression Gene Expression Regulation, Neoplastic Humans Male Middle Aged Programmed Cell Death 1 Receptor / immunology Tumor Microenvironment / genetics Tumor Microenvironment / immunology B7-H1 Antigen CD274 protein, human Immune Checkpoint Inhibitors PDCD1 protein, human Programmed Cell Death 1 Receptor Nivolumab
PMC8511698
34659249
Case Report: Immune and Genomic Characteristics Associated With Hyperprogression in a Patient With Metastatic Deficient Mismatch Repair Gastrointestinal Cancer Treated With Anti-PD-1 Antibody
2021